Sutro Biopharma Shares Outstanding 2017-2021 | STRO

Sutro Biopharma shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Sutro Biopharma Annual Shares Outstanding
(Millions of Shares)
2020 33
2019 23
2018 6
2017 0
2016 0
Sutro Biopharma Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 46
2021-03-31 46
2020-12-31 33
2020-09-30 38
2020-06-30 32
2020-03-31 23
2019-12-31 23
2019-09-30 23
2019-06-30 23
2019-03-31 23
2018-12-31 6
2018-09-30 0
2018-06-30 0
2018-03-31 0
2017-12-31
2017-09-30 0
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.865B $0.043B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57